Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%. The suite features 4 new automated SPPS reactors and a dedicated lyophilization suite capable of processing 200L batches.
Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades. The new catalog includes Semaglutide, Tirzepatide, Liraglutide, and 47 novel analogs with purity ≥98% guaranteed by RP-HPLC.
Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%. The suite features 4 new automated SPPS reactors and a dedicated lyophilization suite capable of processing 200L batches.
AODT Peptide has entered a multi-year exclusive supply agreement for three oncology peptide APIs with a leading European pharmaceutical company, valued at over $45M. The agreement covers GMP-grade supply of three proprietary peptide APIs for Phase III clinical trials and commercial launch.
AODT Peptide successfully completed its annual ICH Q7 third-party compliance audit with zero critical findings and only two minor observations, both resolved within 30 days. The audit covered all 8 synthesis suites, the analytical QC laboratory, and the cold-chain logistics center.
The global GLP-1 receptor agonist market is projected to exceed $100 billion by 2030, driven by obesity and type 2 diabetes treatment demand. As a leading GLP-1 peptide manufacturer, AODT Peptide is positioned to support the growing need for high-purity GLP-1 APIs and analogs.
Our R&D team has published a peer-reviewed paper in the Journal of Peptide Science describing our proprietary continuous-flow synthesis platform, which reduces synthesis time by 40% and improves yield for complex long-chain peptides (>40 amino acids). The platform is now available for custom synthesis projects.
Join 5,000+ pharmaceutical and biotech professionals who receive our monthly newsletter — covering product launches, regulatory updates, and industry insights.
Monthly digest, no spam. Unsubscribe anytime.
We use cookies
We use essential cookies to make our site work, and optional analytics & preference cookies to improve your experience. See our Cookie Policy for details.